U.S., Feb. 11 -- ClinicalTrials.gov registry received information related to the study (NCT07401121) titled 'Safety and Tolerability Study of CTx1000 In Participants With Amyotrophic Lateral Sclerosis' on Dec. 10, 2025.
Brief Summary: This clinical study is in participants with Amyotrophic Lateral Sclerosis and is designed to evaluate the safety and tolerability of the gene therapy CTx1000.
Study Start Date: Jan. 12
Study Type: INTERVENTIONAL
Condition:
ALS (Amyotrophic Lateral Sclerosis)
Intervention:
DRUG: AAV9 Gene therapy
Single dose gene therapy
Recruitment Status: RECRUITING
Sponsor: Celosia Therapeutics Pty Ltd
Disclaimer: Curated by HT Syndication....